(via TheNewswire)

Vancouver, British Columbia – TheNewswire - July 28, 2026 – Aequus Pharmaceuticals Inc. (TSXV: AQS) (the “Company”) announces that Giovanni Di Genova resigned as a director of the Company effective May 7, 2026.

The Company also announces that Doug Janzen resigned as Chief Executive Officer and a director of the Company, and Marc Lustig resigned as a director of the Company, in each case effective July 27, 2026.

The Company previously received a letter dated December 20, 2025, from Mr. Janzen demanding payment of amounts allegedly owing under certain promissory notes and providing notice of default. The Company acknowledged receipt of the demand. As of the date of this news release, the amount claimed under the demand, being $6,514,919, remains unpaid.

The Company thanks Mr. Di Genova,  Mr. Janzen and Mr. Lustig for their contributions and service to the Company.

ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a Canadian reporting issuer whose securities are currently subject to a cease trade order.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Email: accounting@aequuspharma.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2026 TheNewswire - All rights reserved.